ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Bayer AG (PK)

Bayer AG (PK) (BAYZF)

29.4888
-0.2612
(-0.88%)
Closed July 30 4:00PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
29.4888
Bid
28.97
Ask
30.19
Volume
2,635
29.4347 Day's Range 29.72
26.91 52 Week Range 58.933
Market Cap
Previous Close
29.75
Open
29.72
Last Trade
280
@
29.4888
Last Trade Time
Financial Volume
$ 77,794
VWAP
29.5234
Average Volume (3m)
4,797
Shares Outstanding
982,424,082
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
47.64B
Net Profit
-2.94B

About Bayer AG (PK)

Sector
Chems, Allied Pds-whsl, Nec
Industry
Chemicals & Allied Products
Website
Headquarters
Leverkusen, Deu
Founded
1998
Bayer AG (PK) is listed in the Chems, Allied Pds-whsl sector of the OTCMarkets with ticker BAYZF. The last closing price for Bayer (PK) was $29.75. Over the last year, Bayer (PK) shares have traded in a share price range of $ 26.91 to $ 58.933.

Bayer (PK) currently has 982,424,082 shares outstanding. The market capitalization of Bayer (PK) is $29.23 billion.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0212-0.071840054218929.5129.7529.0363176329.27583652CS
41.47385.2607531679528.01529.7527.1549531028.49873524CS
12-0.7512-2.4841269841330.2431.927.1549479729.47713128CS
26-3.7512-11.28519855633.2433.426.912391729.86639276CS
52-28.8412-49.444882564758.3358.93326.913589342.37162432CS
156-32.0512-52.081897952661.5474.3426.912099049.54219744CS
260-37.5112-55.98686567166786.3526.911557952.74152659CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BRDSQBird Global Inc (CE)
$ 0.001
(99,900.00%)
23.38k
COGDFCompass Gold Corporation (PK)
$ 0.0491
(12,175.00%)
3k
ASAPQWaitr Holdings Inc (CE)
$ 0.0001
(9,900.00%)
802
AEGYAlternative Energy Partners Inc (CE)
$ 0.0001
(9,900.00%)
1.13M
FONUFONU2 Inc (PK)
$ 0.0001
(9,900.00%)
350k
AMPEAmpio Pharmaceuticals Inc (CE)
$ 0.000001
(-99.91%)
6.81k
WIRXWireless Xcessories Group Inc (CE)
$ 0.000001
(-99.86%)
200
QBIOQ BioMed Inc (CE)
$ 0.000001
(-99.80%)
2.5k
GLBRGlobal Brokerage Inc (CE)
$ 0.000001
(-99.50%)
520
VIAOYVIA optronics AG (CE)
$ 0.0009
(-99.18%)
1.24k
HMBLHUMBL Inc (PK)
$ 0.00026
(4.00%)
135.19M
HIRUHiru Corporation (PK)
$ 0.0038
(46.15%)
126.45M
DPLSDarkPulse Inc (PK)
$ 0.0008
(-11.11%)
95.28M
AITXArtificial Intelligence Technology Solutions Inc (PK)
$ 0.00406
(-4.47%)
89.86M
UBQUUbiquitech Software Corp (PK)
$ 0.000001
(-99.00%)
75.14M

BAYZF Discussion

View Posts
Pastortec Pastortec 3 months ago
BAYER i recommend buy VOIS. The company that sell the stocks sell with them all its patents and one of them can influence with certain on your future sales.
πŸ‘οΈ0
mm41 mm41 5 months ago
Negative News without end. The stock price is falling like a rock as frustrated investors dump their stocks from their portfolios. Does that even make sense?
I would say NO. The company will certainly survive the crisis because it has had proven and real products for 100 years.
Well, now experts and analysts are making the rounds, and other Internet influencers are also propagating the last rites. So I'm buying. ISIN: DE000BAY0017 | WKN: BAY001
πŸ‘οΈ0
mm41 mm41 5 months ago
Negative News without end. The stock price is falling like a rock as frustrated investors dump their stocks from their portfolios. Does that even make sense?
I would say NO. The company will certainly survive the crisis because it has had proven and real products for 100 years.
Well, now experts and analysts are making the rounds, and other Internet influencers are also propagating the last rites. So I'm buying. ISIN: DE000BAY0017 | WKN: BAY001
πŸ‘οΈ0
mm41 mm41 5 months ago
I`m bullish
πŸ‘οΈ0
mm41 mm41 5 months ago
I`m bullish
πŸ‘οΈ0
mm41 mm41 5 months ago
The cheapest blue-chip stock . buy for a good long term
πŸ‘οΈ0
debunker1 debunker1 6 years ago
Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.
πŸ‘οΈ0
trendmkr trendmkr 9 years ago
A Look at the Science Behind Bayer’s Latest Buy

http://marketexclusive.com/a-look-at-the-science-behind-bayers-latest-buy/1194/
πŸ‘οΈ0
MasterofCoin15 MasterofCoin15 9 years ago
this stock don't play... up 50% since last year..
πŸ‘οΈ0
dragonball dragonball 15 years ago
how come this board is dead?
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
Yes, hope so eom
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
well it must be good if it made it to phase 3
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
maybe its a cancer drug? dont know oncological maybe. ?
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
very true. I will be picking up 100 shares and just letting it ride you think it might dip a bit?
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
no,if Management has time to talk to me, they are not busy enough. I will let them be the PPS is good imo

πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
what exactly does nexevar do?
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
seriously though this looks like a pretty good company have you spoken to management?
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
then you are about to move on up, to the east side to a deluxe apartment in the sky when you take this new brand of bayer pill lol
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
yes i do

πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
Knowing your alias you take the dollar store brand lol

j/k
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
Is this bayer like the one in my medicine cabinet
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
Bayer And Onyx Say 39% Progress On Phase III Nexavar Trial In Patients With Advanced Kidney Cancer - Quick Facts [BAY]

11/3/2005 4:19:02 AM Bayer Pharmaceuticals Corp. (BAY) and Onyx Pharmaceuticals, Inc. (ONXX) provided an update on the Nexavar Tablets Phase III trial in patients with advanced renal cell carcinoma or kidney cancer.

Based on announced interim analysis, there was an estimated 39% improvement in survival for patients receiving Nexavar versus those receiving placebo.

The final survival analysis, which is planned when 540 events have occurred, is not expected for some time. Therefore, while the findings of the interim analysis did not reach statistical significance, these early results suggest a favorable survival trend for patients who received Nexavar.

http://realtimetraders.com/sp/breakingnews.asp?vid=9625264



πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock